Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance
2019; Lippincott Williams & Wilkins; Volume: 41; Issue: 8 Linguagem: Inglês
10.1097/mph.0000000000001440
ISSN1536-3678
AutoresMegan Rose Paul, Victor Wong, Paula Aristizabal, Dennis John Kuo,
Tópico(s)Lymphoma Diagnosis and Treatment
ResumoInotuzumab ozogamicin is a novel antibody-drug conjugate that targets CD22, a common antigen on pre-B acute lymphoblastic leukemia cells.A 7-year-old boy with pre-B acute lymphoblastic leukemia in his second relapse was given 2 cycles of inotuzumab ozogamicin. He responded morphologically with a negative bone marrow evaluation. However, he relapsed in cycle 3 of therapy with a loss of CD22 expression on his lymphoblast population.To our knowledge, this is the first published case of CD22 expression loss as a mechanism of therapy resistance for inotuzumab ozogamicin.
Referência(s)